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Helicobacter pylori, an etiological agent of active chronic gastritis and peptic ulcer disease, is now 
considered to be an invasive enteropathogen. Anti-adhesion and anti-internalization are new strategies 
for prevention and treatment of bacterial infection including the alternative of medicinal plants. In this 
study, four parts of Kaempferia parviflora’s extracts composing of volatile oil, hexane, ethyl acetate and 
methanol were examined for their antibacterial and anti-internalization activities of H. pylori against 
HEp-2 cells. All extracts except volatile oil showed significant antibacterial activity and had a minimum 
inhibitory concentration (MIC) ranging from 32 - 64 µg/ml. The most active extract of ethyl acetate 
exhibited significant anti-internalization activity which corresponded to dose and time of treatment. 
Moreover, K. parviflora’s ethyl acetate extract could significantly inhibit the invasion of both H. pylori 
virulent strains (cagA+) and non-virulent strains (cagA-) in HEp-2 cells. Thus, K. parviflora is one of the 
effective herbs for potential prevention and treatment of H. pylori infection. 
 





Helicobacter pylori is a causative agent in gastroduodenal 
diseases such as chronic gastritis, peptic ulceration, 
gastric adenocarcinoma and mucosa-associated lymphoid 
tissue lymphoma (MALT) (Graham, 1997; Raus et al., 
1987; Wotherspoon et al., 1993). Its colonization most 
likely occurs during childhood and affects about half of 
the world’s population by majority of fecal-oral trans-
mission (Blaser, 1999; Covacci et al., 1999). The H. pylori 
infection is successfully treated by a combination of a 
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Abbreviations: MIC, Minimum inhibitory concentration; CFU, 
colony forming unit; cagA+, Helicobacter pylori virulent strains; 
cagA-, Helicobacter pylori non-virulent strains. 
clarithromycin, amoxicillin, or metronidazole. However, 
the incidence of antibiotic resistance has increased, 
causing the disease eradication to fail. According to 
previous reports, H. pylori has been considered an intra-
cellular microorganism which may be responsible for the 
chronic infection and the development of gastric cancer 
(Anderson and Holck, 1990; Evans et al., 1992; Wilkinson 
et al., 1998). The histomicrobiological study from 
transmission electron microscope revealed spiral H. pylori in 
the gastric lumen and between the gastric epithelium 
cells and coccoid H. pylori within the endocytotic vesicles 
in the apical cytoplasmic part of the epithelial cells, which 
confirmed the internalization capability of this organism 
(Ozbek et al., 2009). The adherence and invasion of H. 
pylori in gastric epithelial cells triggers the process of 
immune response and virulence properties including 
secretion of pro-inflammatory cytokines, cell proliferation, 





et al., 2006). Therefore, a non-antibiotic agent, capable of 
inhibiting the growth of H. pylori and the invasion to the 
target cells may be an effective way for preventing or 
treating the infections. Medicinal plants are useful 
alternative source of novel drugs containing various 
pharmacological activities such as antimicrobial activities, 
anti-inflammatory and anti-ulcerogenic effects. Kaempferia 
parviflora Wall. Ex Baker or Kra-chai-dam belonging to 
the Zingiberaceae family is one of the attractive plants for 
the reasons of its anti-gastric ulcer activity (Rujjanawate 
et al., 2005). It has long been used in Thai traditional 
medicine for rectifying male impotence, body pains, relief 
symptoms of colic and gastrointestinal upset. The extract 
could reduce the time in the first 10 min of rat courtship 
behavior with no toxicity (Sudwan et al., 2006). Further-
more, the extracts and flavone derivatives from the 
rhizome of K. parviflora could suppress function of multidrug 
resistance associated-proteins (MRP), in addition to P-
glycoprotein, in cancer cells, (Patanasethanont et al., 
2006; Patanasethanont et al., 2007).  
In this study, the anti-Helicobacter pylori activity of 
extracts from K. parviflora were investigated. In addition, 
internalization ability of H. pylori against HEp-2 cells was 
compared between the presence and absence of extracts 
using gentamicin internalization assay. 
 
 
MATERIALS AND METHODS 
 
Plant materials and extraction 
 
K. parviflora Wall. Ex Baker were bought from a Thai traditional 
drug store at Pak Klong market in Bangkok, Thailand. The plant 
material was identified by one of the authors (E. Saifah, Chulalongkorn 
University). A voucher specimen (No. ES280306) was deposited at 
the herbarium of the Faculty of Pharmaceutical Sciences, 
Chulalongkorn University, Thailand. One kilogram of roughly ground 
air-dried plant material was extracted for 3 h by hydrodistillation 
method and volatile oil was collected. The residue was further 
extracted twice for 48 h with 200 ml of hexane at room temperature. 
The combined extracts were filtered and concentrated by evaporation 
at 40°C until dryness. The residue was dissolved in 200 ml of ethyl 
acetate and extracted twice for 48 h at room temperature. The 
filtrate was evaporated to dryness as described. The remaining 
residue was finally extracted twice for 48 h at room temperature 
with 200 ml of methanol. After filtration, the extract was evaporated 
similarly to dryness. The yield obtained under each extraction type 
was 0.129% for volatile oil, 0.046% for hexane, 0.721% for ethyl 
acetate and 1.27% for methanol. Each extract was dissolved at 
0.25 g/ml with dimethyl sulfoxide (DMSO) except for hexane extract 
at 0.125 g/ml. These stock solutions were filtrated through 0.2 µm 
Millipore and stored at -20°C before use.  
 
 
Bacterial strains and culture condition 
 
Three reference strains of H. pylori (ATCC 43504, ATCC 43526 and 
ATCC 51932) were purchased from the American Type Culture 
Collection (Rockville, MD).  Nine clinical isolated were a kind gift 
from Dr. Ratha-korn Vilaichone, Division of Gastroenterology, 
Department of Medicine, Thammasat University Hospital  (C7, C53, 
742, 818, 820, 849, 867, 912 and 949)  and 2 clinical isolates were  




purchased from Department of Medicinal Sciences, Ministry of 
Public Health, Thailand (DMST 20165 and DMST 20885). The 
bacteria were grown on brain heart infusion agar containing 5% 
(v/v) sheep blood and were incubated at 37°C under microaerophilic 
conditions (N2, 85%; O2, 5%; CO2, 10%) using gas generating kit 
(Oxoid, UK) for 3-5 days.  
 
 
Minimum inhibitory concentrations 
 
Minimum inhibitory concentrations (MIC) were determined, in duplicate, 
by an agar dilution method following the National Committee for 
Clinical Laboratory Standards guidelines using Mueller-Hinton agar 
with 5% (v/v) sheep blood. The concentrations of the extracts were 
ranging from 16 - 2,048 µg/ml using two-fold serial dilutions. A 72-h 
bacterial colony of H. pylori strains were suspended in 0.85% NaCl 
to a turbidity of McFarland standard 2 (107 - 108 CFU/ml). Sub-
sequently, three microlitres of each inoculum was spotted on each 
plate and incubated as described for 3 days. The MIC was defined 
as the lowest concentration of each extract at which no visible 
growth was observed. 
 
 
Culture of HEp-2 cells 
 
The HEp-2 cells (kindly provided by Dr. Pornthep Tiensiwakul, Faculty 
of Allied Health Sciences, Chulalongkorn University, Thailand) were 
grown on tissue culture plasticware in Dulbecco’s modified Eagle’s 
medium (DMEM; Life Technologies Inc., Rockville, Md) supple-
mented with 10% (v/v) fetal bovine serum and 1% (v/v)   antibiotic-
antimycotic solution (Gibco BRL Laboratories, Grand Island, N.Y.) 
at 37°C in 5% CO2 with 80% humidity. 
 
 
Gentamicin internalization assay  
 
HEp-2 cells were washed two times with Hank’s balanced salt 
solution (HBSS) treated with trypsin, and counted. Approximately 
1X106 cells were seeded on six wells tissue culture plates and 
incubated overnight to obtain 80% confluency. Each well was 
washed twice with HBSS and added with DMEM containing no 
antibiotics. H. pylori was harvested and resuspended into HBSS 
(about 108 CFU/ml). 100 µl of bacterial suspension was added to 
each well in the absence or presence of the extracts and incubated 
for 3 h. After incubation, the cells were gently washed two times 
with HBSS, and treated with HBSS containing 100 µg/ml gentamicin 
and incubated for one hour to kill extracellular bacteria. HEp-2 
monolayers were then washed three times with HBSS and treated 
with distilled water for 10 min to release intracellular bacteria. Serial 
10-fold dilutions of the lysed monolayer were placed on brain heart 
infusion agar supplemented with 5% (v/v) sheep blood, incubated 
as previously for 3 - 5 days to determine the number of viable 





All experiments were carried out independently in duplicate experi-
ments. The inhibition of internalization by various K. parviflora’s 
extracts and various concentrations of K. parviflora ethyl acetate 
extract were evaluated by one way analysis of variance (ANOVA). 
While, the effect of K. parviflora’s extracts on internalization activities of 
each H. pylori strains and the effect of treatment time were 
compared under treated and untreated condition using the student’s 
t test. Statistical significance was accepted at the P = 0.05 level. 




Table 1. Minimum inhibitory concentrations (MICs: 
µg/ml) of Kaempferia parviflora’s extracts against 13 
Helicobacter pylori strains. 
 
Extracts MIC (µg/ml) 
Volatile oil 1,024 
Hexane extract 64 
Ethylacetate extract 32 






Minimum inhibitory concentrations   
 
Four parts of K. parviflora’s extracts, volatile oil, hexane, 
ethyl acetate and methanol, were screened in vitro for the 
anti-Helicobacter pylori actions. As summarized in Table 
1, the strongest growth inhibition against all thirteen test 
strains of H. pylori was ethyl acetate extract with MIC of 
32µg/ml. The MICs of the extracts from hexane and 




Internalization assay  
 
All K. parviflora’s extracts exhibited anti-internalization 
activities against HEp-2 cells at the concentration of MIC 
except volatile oil (Figure 1). It was found that volatile oil 
affected the cellular structure and adherence ability of 
HEp-2 cells. HEp-2 cells were deformity and detached 
from the culture well. Moreover, volatile oil inhibited the 
growth of H. pylori, no viable bacteria was detected when 
incubated the volatile oil with H. pylori for 3 h (data not 
shown). However, the anti- internalization activities were 
not significantly different between hexane, ethyl acetate 
and methanol extracts (Figure 1; P > 0.05). In order to 
determine the optimum treatment condition, the ethyl 
acetate extract with the highest MIC was tested for the 
inhibitory effect on H. pylori internalization at various 
times and concentrations. It was found that the bacterial 
conferred higher capability to enter into the cells at the 
extended incubation times (Figure 2). However, ethyl 
acetate extract of K. parviflora still maintained effective 
anti-internalization activity upon H. pylori during the 
longer treatment period. The number of treated intra-
cellular H. pylori was significantly lower than the 
untreated at 3, 6, 12 and 24 h (Figure 2; P < 0.05). Due to 
the number of bacterial viability was decreased during the 
longer treatment time (data not shown), the effect of dose 
was examined at 3 h according to low effect of growth 
inhibition. The invasion efficiency had been shown to 
respond to the concentrations of K. parviflora’s ethyl 
acetate extract in the range from 8 to 128 µg/ml (Figure 
3). The proportions of intracellular bacteria were signifi-





0.05). The percent of internalized bacteria was 59.28, 
42.96, 32.34, 11.63 and 8.47% at 8, 16, 32, 64 and 128 
µg/ml, respectively. However, K. parviflora’s ethyl acetate 
extract of 128 µg/ml markedly effected the growth of H. 
pylori, the number of viable bacteria dramatically reduced 
about 100 fold from the initial inoculum (data not shown). 
Thus, the optimum treatment condition of K. parviflora’s 
ethyl acetate extract against H. pylori internalization into 
HEp-2 cells was selected at 64 µg/ml at 3 h of incubation. 
Comparison of the effect of K. parviflora’s ethyl acetate 
extract between five H. pylori strains (3 cagA+ strains of 
ATCC 43504, ATCC 43526 and clinical isolated no. 820 
and 2 cagA- strains of ATCC 51932 and DMST 20165) 
for the anti-internalization activity against HEp-2 cells was 
demonstrated in Figure 4. The extract was significantly 
inhibited the invasion of all tested H. pylori strains (P < 
0.05). The bacterial invasion activities in overall treated 
strains were reduced more than 75% compared to the 





H. pylori colonization of the human stomach leads to a 
chronic infection associated with duodenal and gastric 
ulcers (Logan, 1994; Forman, 1996). In view of the rapid 
increase of bacterial resistance to antibiotic, medicinal 
plants are now more explored for their bioactivity. Here, 
we demonstrated the anti-Helicobacter pylori activity of K. 
parviflora, a Thai traditional herb for treatment of colic 
disorder and gastric ulcer (Rujjanawate et al., 2005). The 
ethyl acetate extract of K. parviflora exhibited the highest 
MIC of 32 µg/ml against H. pylori. K. parviflora had been 
reported to possess antibacterial, anti-allergic activities 
(Tewtrakul and Subhadhirasakul, 2007; Tewtrakul et al., 
2008), anti-peptic ulcer (Rujjanawate et al., 2005), 
antiviral proteases (Sookkongwaree et al., 2006) and anti-
inflammatory activity (Sae-wong et al., 2009). Recently, 
the ethanolic extract of K. parviflora was found to exhibited 
the anti-cancer action against human cholangiocarcinoma 
(Leardkamolkarn et al., 2009). It was suggested that 
some bioactive flavonoids containing in the rhizome of K. 





5,7,4’-trimethoxyflavone and 5,7,3’4’-tetramethoxyflavone 
(Yenjai et al., 2004). Some flavonoids derivatives and 
their metabolite such as genistein, hesperitin, ponciretin, 
irisolidone and cabreuvin displayed anti-Helicobacter 
pylori activity (Bae et al., 1999). 
H. pylori has been proven an intracellular organism in 
both cell lines and human gastric biopsies (Bjorkholm et 
al., 2000). Moreover, it was found that the antibiotic 
resistance in H. pylori was associated with higher inter-
nalization activity due to the ability to escape from antibiotic  




































































Figure 1. Internalization assay of H. pylori-infected HEp-2 cells in the absence or presence of K. 
parviflora’s extracts at 3 h of incubation. The extracts were added at the concentration of the MIC. 
Results are presented as the proportion of internalized bacteria versus control.  The proportion of 
internalized bacteria was calculated as the rate of the number of internalized bacteria divided by 
the bacterial inoculum. Data are presented as mean±SD of separate duplicate experiments with 
two wells per experiment and duplicate plate counts from each well. The significant difference 



























Figure 2. Quantitative internalization assay in HEp-2 cells incubated with H. pylori ATCC 
43504 with and without ethyl acetate extract of K. parviflora at 3, 6, 12 and 24 h. The 
concentration of K. parviflora’ s ethyl acetate extract was used at 32 µg/ml. The number of 
internalized H. pylori was assessed by log CFU/ml. Data are presented as mean±SD of 
separate duplicate experiments with two wells per experiment and duplicate plate counts 




treatment. The close relationship between the elevated 
invading efficiency and clarithromycin resistance was 
investigated (Lai et al., 2006). Therefore, anti-invasion 
agents may open a new avenue  for  effective  prevention  
































Figure 3. The effect of various concentrations of K. parviflora’s ethyl acetate extracts on H. pylori 
ATCC 43504 internalization of HEp-2 cells at 3 h of incubation. The data are presented as mean±SD 
of independent duplicate experiments with two wells per experiment and duplicate plate counts from 


































* * * * * 
 
 
Figure 4. The effect of K. parviflora’s ethyl acetate extract on internalization of different strains of 
H. pylori into HEp-2 cells. HEp-2 cells were co-cultured with H. pylori in the absence and presence 
of 64 µg/ml of the extract for 3 h. Data are presented as mean±SD of independent duplicate 
experiments with two wells per experiment and duplicate plate counts from each well. The 




and treating infections. In the present study, the anti-
internalization activities of H. pylori into HEp-2 cells were 
observed in K. parviflora extracted with hexane, ethyl 
acetate and methanol. The invasion frequency of H. 
pylori against HEp-2 cells was accelerated with time. This 
correlated with previous study which found that HEp-2 
cells penetration of H. pylori were inoculum and time 
dependent (Wilkinson et al., 1998). Although, higher 
number of internalized H. pylori was observed after the 
extended period, K. parviflora’s ethyl acetate extract still 
significantly inhibited the invasion ability.  Moreover, the 





dependent pattern. The inhibitory activity was indepen-
dent of the strain virulence. Both cagA+ and cagA- strains 
were inhibited by K. parviflora’s ethyl acetate extract in 
the same manner. The anti-internalization activities of K. 
parviflora implicated one possible mechanism for anti-
peptic ulcer of this plant. Oral administration of K. 
parviflora at 30, 60 and 120 mg/kg significantly inhibited 
gastric ulcer formation in rats. Its gastroprotective potential 
was suggested to be related partly to preservation of 
gastric mucus secretion (Rujjanawate et al., 2005). So, 
blocking the H. pylori invasion by K. parviflora was 
suggested to enhance the curing rate of H. pylori and 
could synergize the conventional antibiotic treatment.  
However, the anti-invasion mechanism of the K. parviflora’s 
extract has to be deeply elucidated by both biochemical 
and genetically based studies.  
In conclusion, to achieve the therapy against H. pylori, 
both extracellular and intracellular organism have to be 
eliminated. In this regard, K. parviflora may be considered 
in addition to current antimicrobial therapy for H. pylori 
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